FULC Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Fulcrum Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.74 |
| 52 Week High | US$13.70 |
| 52 Week Low | US$3.14 |
| Beta | 2.28 |
| 11 Month Change | 9.68% |
| 3 Month Change | 25.84% |
| 1 Year Change | 68.51% |
| 33 Year Change | -64.58% |
| 5 Year Change | -9.48% |
| Change since IPO | -27.85% |
Recent News & Updates
Recent updates
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Jul 12
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
Nov 17We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Aug 11Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Jul 11Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Jul 05Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Jun 27These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
May 10Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
Sep 03Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results
Aug 12News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
Aug 11Shareholder Returns
| FULC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.3% | 2.1% | 0.1% |
| 1Y | 68.5% | 18.8% | 24.9% |
Return vs Industry: FULC exceeded the US Pharmaceuticals industry which returned 19% over the past year.
Return vs Market: FULC exceeded the US Market which returned 25.9% over the past year.
Price Volatility
| FULC volatility | |
|---|---|
| FULC Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: FULC's share price has been volatile over the past 3 months.
Volatility Over Time: FULC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 76 | Alex Sapir | www.fulcrumtx.com |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.
Fulcrum Therapeutics, Inc. Fundamentals Summary
| FULC fundamental statistics | |
|---|---|
| Market cap | US$572.22m |
| Earnings (TTM) | -US$20.23m |
| Revenue (TTM) | US$81.63m |
7.4x
P/S Ratio-30.0x
P/E RatioIs FULC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FULC income statement (TTM) | |
|---|---|
| Revenue | US$81.63m |
| Cost of Revenue | US$74.27m |
| Gross Profit | US$7.36m |
| Other Expenses | US$27.59m |
| Earnings | -US$20.23m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 9.02% |
| Net Profit Margin | -24.79% |
| Debt/Equity Ratio | 0% |
How did FULC perform over the long term?
See historical performance and comparison